Why Grail Could Be the Sleeper Stock Everyone's About to Notice
Grail is on a quest to win in a $50 billion market.
Why Grail Could Be the Sleeper Stock Everyone's About to Notice
Overview
Ask some people about Grail (NASDAQ: GRAL), and a Monty Python movie will probably come to mind. The innovative pioneer of liquid biopsies (blood tests that can detect cancer) continues to fly under the radar screen for many investors.
That's understandable to some extent. After all, Grail is almost a small-cap stock, with a market cap hovering around $2.6 billion. It's easy to ignore or overlook. But could Grail be a sleeper stock everyone's about to notice?
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
- 51% of U.S. adults say the American Dream is out of reach for most people right now: CNBC survey
- A massive 16% market swing just rocked South Korea over 24 hours. The retail ‘ants’ holding the wheel are driving dangerously.
- I’m 60, retired with $3 million. My fiancée, 55, has $1 million but plans to work for the next 10 years. Are we compatible?
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
